Nintendo Wii therapy can help improve balance in children with cerebral palsy


Therapy based on the Nintendo® Wii Balance Board can help improve balance in children with cerebral palsy, according to an analysis published in Developmental Medicine & Child Neurology.

For the analysis, researchers from the University of Jaén, in Andalusia, Spain examined data from all relevant randomized controlled trial published to date. In 11 trials with 270 children with cerebral palsy, there was very low-quality evidence of a large effect of Nintendo® Wii therapy on functional balance (compared with no intervention) and moderate-quality evidence for a benefit to using Nintendo® Wii therapy plus conventional physical therapy (compared with conventional physical therapy alone) in sessions of approximately 30 minutes and interventions lasting longer than 3 weeks.

For dynamic balance (involving balance while in motion or when switching positions), investigators found very low-quality evidence for a medium effect for using Nintendo® Wii therapy plus conventional physical therapy vs. conventional physical therapy alone.

Our results suggest that Nintendo® Wii therapy may be a useful tool that can be included in neurorehabilitation physiotherapy protocols to improve balance in children with cerebral palsy. Virtual reality-based rehabilitation using Nintendo® Wii is considered a multi-sensory and active therapy that encourages the child’s participation, increasing motivation and adherence to therapy due to its playful nature. In addition, it is a low-cost tool that can be used at home for therapeutic purposes, a fact that is of great relevance during the COVID-19 pandemic.”

Esteban Obrero-Gaitán, PT, PhD, Study Corresponding Author, Wiley

Journal reference:

Montoro-Cárdenas, D., et al. (2021) Nintendo Wii Balance Board therapy for postural control in children with cerebral palsy: a systematic review and meta‐analysis. Developmental Medicine & Child Neurology.

Products You May Like

Articles You May Like

CURSO: Alimentación y Fenómeno Inmigratorio
Solabia-Algatech launches whole algae β-glucan ingredient
Coca-Cola reveals early learnings from Topo Chico Hard Seltzer launch
Peanut Allergy-Friendly MLB Baseball Games
US FDA approves first interchangeable biosimilar
FDA Alerts Patients and Health Care Professionals About Clinical Trial Results Showing an Increased Risk of Death Associated with Pepaxto (melphalan flufenamide)

Leave a Reply

Your email address will not be published. Required fields are marked *